Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

Table 2 Monthly HAE attack rate reduction from baseline with lanadelumab treatment in HELP and HELP OLE

	Mean (SD) attack rate, attacks/4 weeks		Mean (SD) % change
	Baseline	Treatment period	Mean (SD) % change
HELP
White (n = 74)	3.67 (2.25)	0.43 (0.66)	− 88.18 (17.18)
Black/African American (n = 8)^a	2.03 (1.51)	0.48 (0.44)	− 79.03 (19.42)
Asian (n = 2)^b	2.41 (1.99)	1.74 (0.11)	12.61 (97.59)^c
Non-Hispanic/non-Latino (n = 77)	3.50 (2.20)	0.49 (0.68)	− 84.11 (26.25)
Hispanic/Latino (n = 6)	3.70 (2.69)	0.31 (0.51)	− 92.53 (12.68)
HELP OLE
White (n = 198)	3.13 (2.70)	0.25 (0.56)	− 87.74 (69.44)
Black/African American (n = 10)	1.82 (1.61)	0.26 (0.42)	− 78.94 (34.04)
Asian (n = 2)	2.41 (1.99)	0.34 (0.14)	− 75.10 (26.37)
Other (n = 2)	1.38 (0.65)	0.03 (0.04)	− 98.56 (2.04)
Non-Hispanic/non-Latino (n = 198)	3.02 (2.66)	0.26 (0.57)	− 86.60 (70.11)
Hispanic/Latino (n = 13)	3.37 (2.72)	0.06 (0.09)	− 97.66 (3.89)

Attack rates for the HELP study are for the lanadelumab treatment groups together (placebo is excluded). The data for all lanadelumab doses in the HELP study are pooled
HAE hereditary angioedema, OLE open-label extension, q2w every 2 weeks, q4w every 4 weeks
^aOnly 1 Black/African American patient was in the lanadelumab 300 mg q2w treatment group
^bBoth of the Asian patients were in the lanadelumab 150 mg q4w treatment group
^cOne patient had an increase in attack rate with treatment

ISSN: 1710-1492